Dynavax Technologies (NASDAQ:DVAX) Reaches New 12-Month Low After Analyst Downgrade

Dynavax Technologies Co. (NASDAQ:DVAX) shares reached a new 52-week low on Thursday after JMP Securities lowered their price target on the stock from $33.00 to $31.00. JMP Securities currently has a market outperform rating on the stock. Dynavax Technologies traded as low as $9.62 and last traded at $9.72, with a volume of 6232072 shares traded. The stock had previously closed at $10.92.

Several other analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group cut their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a report on Thursday, April 17th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $24.00.

Hedge Funds Weigh In On Dynavax Technologies

Several institutional investors and hedge funds have recently bought and sold shares of DVAX. DekaBank Deutsche Girozentrale acquired a new stake in shares of Dynavax Technologies during the first quarter worth approximately $30,000. Russell Investments Group Ltd. boosted its stake in shares of Dynavax Technologies by 96.5% during the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Dynavax Technologies in the fourth quarter worth $35,000. Finally, GAMMA Investing LLC raised its holdings in shares of Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Trading Down 2.9 %

The business has a 50-day moving average of $12.24 and a 200-day moving average of $12.55. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 52.28 and a beta of 1.26.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $68.16 million during the quarter, compared to the consensus estimate of $70.01 million. As a group, research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.